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CObjective: To further examine the reliability, validity and responsive-
ness of the uterine fibroid symptomandquality-of-life (UFS-QOL) ques-
tionnaire among women with and without uterine fibroids.
Methods: Amulticenter, non-randomized, prospective studywas con-
ducted with women undergoing treatment for uterine fibroids (fibroid
treatment group [FTG]) and normal controls (normal control group
[NCG]). Women in the FTG were recruited when they were scheduled
for treatment; women in the NCG were recruited during their annual
exam. Participants completed the UFS-QOL and a short form 36 health
survey (SF-36) at enrollment and at 6 and 12 months. Descriptive sta-
tistics, Cronbach’s alpha, Spearman’s correlations, t tests, and general
linear models were used to analyze the internal consistency and test–
retest reliability, concurrent and discriminant validity, and responsive-
ness of the UFS-QOL. Results: There were 89 NCG and 234 FTG women
ho completed the study. Mean age was 43.1 years for FTG and 40.8 for
CG (P 0.001). The FTG reported significantly greater symptom sever- O
Sourc
al So
doi:10.1016/j.jval.2011.07.007ty and worse health-related quality of life (HRQL) than the NCG (all
FS-QOL subscales P  0.001). The UFS-QOL subscales were signifi-
antly correlated in the expected direction and magnitude with each
F-36 subscale in the FTG, indicating acceptable concurrent validity.
ronbach’s alphas were 0.73 to 0.97, reflecting adequate internal con-
istency. EachUFS-QOL subscalewas responsive to changes after treat-
ent in the FTG with effect sizes ranging between 1.1 and 2.35. The
FS-QOL remained stable in the NCG during the 1 year follow-up.
onclusion: The UFS-QOL is a valid and reliable measure to assess
ymptoms and HRQL in women with uterine fibroids and is highly
esponsive to treatment-related changes.
eywords: health-related quality of life, Patient-reported outcomes,
ymptoms, Uterine fibroids.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Uterine leiomyomata, or fibroids, are among the most common
benign tumors of the female reproductive tract, with fibroids iden-
tified in up to 77% of hysterectomy specimens [1]. Nearly half of
women with uterine fibroids have heavy bleeding [2,3]; many also
report moderate to severe abdominal pain [4], urinary frequency
and urgency, low back pain, and pain during intercourse [2].
Women with severe bleeding may stay close to a restroom on
menstruating days leading to disruption in work productivity,
sleep, and social activities [2]. As symptoms and their impact on
ealth-related quality of life (HRQL) and activities of daily living
re the primary indications for uterine fibroid therapy, patient-
eported outcome measures are the most appropriate tools to
easure the impact and outcomes of interventions.
The uterine fibroid symptom and quality-of-life questionnaire
UFS-QOL) is a fibroid-specific symptom and quality of life ques-
ionnaire, developed to assess outcomes fromfibroid therapies [5].
he initial validation demonstrated its ability to discriminate
omen without fibroids from women with fibroids and from pa-
* Address correspondence to:Karin S. Coyne, PhD,MPH,United Bio
600, Bethesda, MD 20814.
E-mail: karin.coyne@unitedbiosource.com.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.tients with varying degrees of fibroid symptoms. However, the
original validation was cross-sectional and responsiveness analy-
ses could not be conducted. Although one study assessed the re-
sponsiveness of the UFS-QOL using a series of patients treated
with magnetic resonance–-guided focused ultrasound surgery [6],
this study did not have normal controls. Because the UFS-QOL has
been used in several fibroid studies [7–10], the purpose of this
study was to further evaluate the reliability, validity, and respon-
siveness of the UFS-QOL among women with and without uterine
fibroids.
Materials and Methods
This was a multicenter comparative, prospective outcome study
of women undergoing treatment for uterine fibroids, with a nor-
mal control group for which the clinical findings have been previ-
ously described [11]. Patients undergoing fibroid treatment were
enrolled at three university medical centers and one academic
militarymedical center; womenwithout fibroids (normal controls)
were recruited at three of these centers along with two private
e Corporation, OutcomesResearch, 7101WisconsinAvenue, Suite
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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136 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 5 – 1 4 2practices in the Washington, DC metropolitan area. Each center’s
Institutional Review Board approved the study. The study was
conducted in compliance with the Health Information Portability
and Accountability Act and the principles outlined in the Declara-
tion of Helsinki. All patients provided written informed consent
for study participation.
Recruitment
Women with uterine fibroids were recruited to participate in this
study after their treatment procedure was scheduled. Each partic-
ipant in the fibroid treatment group (FTG) had a routine history
and physical examination, supplemented with imaging as appro-
priate, to confirm her diagnosis. Women in the normal control
group (NCG) were recruited as they completed routine well-
woman evaluations by their gynecologists. Pre-menopausal
women  30 and  50 years old who were willing to provide writ-
ten informed consent and able to speak and read English were
included in both groups. Additionally, the women in the FTG had
to be scheduled to undergo hysterectomy, myomectomy, or uter-
ine embolization. Women in the NCG had to have no history of
uterine fibroids and a normal gynecologic examination with reg-
ular menstrual cycles at the time of enrollment. Women were
excluded if they were: currently pregnant, had cognitive or psy-
chiatric impairment that would interfere with completing the
questionnaires, had comorbidity with life expectancy less than 1
year, or were an active military duty member.
Questionnaire assessment
All participants completed the UFS-QOL, the medical outcomes
study short form 36 (SF-36), and a brief sociodemographic ques-
tionnaire prior to their scheduled treatment (for FTG) or at enroll-
ment (for NCG). The participants mailed the completed question-
naire packet in a pre-addressed stamped envelope to the data
center.
Follow-up questionnaire packets were mailed to each partici-
pant at 6 and 12 months. The initial study design was to include a
5-year follow-up period; however, due to a limitation of funding,
the study was terminated after 1 year of follow-up. The following
questionnaires were completed at both follow-ups: overall treat-
ment effect (OTE) scale, UFS-QOL (or UFS-QOL-hysterectomy), SF-
36, and a status form, which collected healthcare utilization and
pregnancy status. Each questionnaire is described in greater detail
below. Participants mailed the completed questionnaires in pre-
addressed stamped envelopes to the data center. Each participant
was mailed $20 upon receipt of each questionnaire packet.
Questionnaires utilized in study
UFS-QOL
The UFS-QOL was developed from focus groups of women with
leiomyomata. The final questionnaire consists of an 8-item symp-
tom severity scale and 29 HRQL questions, which comprise the
following six subscales: concern, activities, energy/mood, control,
self-consciousness, and sexual function [5]. Participants are in-
structed to consider their experiences with uterine fibroids during
the previous 3 months. Response options for the symptom sever-
ity subscale range from “not at all” to “a very great deal.” Response
options for the HRQL subscales range from “none of the time” to
“all of the time.” The Symptom Severity subscale and the HRQL
subscale scores of the UFS-QOL are opposite, with higher symp-
tom scores indicating greater symptom severity while higher
HRQL subscale scores indicate better HRQL.UFS-QOL-hysterectomy
Because the wording of the UFS-QOL is based on the presence of
uterine fibroids, this questionnaire was modified to allow women
with hysterectomies to respond. The UFS-QOL-hysterectomy is
the same as the UFS-QOL questionnaire except that the introduc-
tory paragraphwas changed to instruct the participant to consider
each symptom as it relates to how she feels now “after your hyster-
ectomy” as opposed to related to her symptoms of her uterine fi-
broids or menstrual cycle during the previous 3 months. The lead-in to
each question was changed to: “Since your hysterectomy. . .” This is
the first time this questionnaire has been implemented.
Medical outcomes SF-36
The medical outcomes SF-36 is a 36-item self-administered ge-
neric measure designed to assess general health status [12]. The
SF-36 is comprised of the following eight subscales: physical func-
tioning, role-physical, bodily pain, general health, vitality, social
functioning, role-emotional, andmental health; in addition, it also
has two composite scores, the physical component score and
mental component score. Individual items from each subscale are
combined to form a subscale rating and transformed to a 0 to 100
scale. Higher scores indicate better quality of life and the recall
period is 4 weeks. Reference values derived in a healthy popula-
tion, distributed by age and gender, are available [12].
OTE scale
The OTE is an assessment of change in symptoms since the pre-
vious questionnaire completion and was completed at each fol-
low-up visit. The participant indicated on the first question
whether her uterine fibroid symptoms (for the FTG) or menstrual
symptoms (for the NCG) have improved, remained the same, or
worsened since the last visit. If her symptoms improved, she rated
the degree of improvement on a 7-point scale from 1 “almost the
same, hardly better at all” to 7 “a very great deal better.” If her
symptoms worsened, she rated the degree of deterioration on a
7-point scale from1 “almost the same, hardlyworse at all” to7 “a
ery great deal worse.” The OTE was utilized to identify stable pa-
ients for the test–retest reliability analysis and to assess responsive-
ess of theUFS-QOL. Participants scoring1, 0, or 1were considered
unchanged”; those scoring less than 1 were considered “worse,”
nd those scoring greater than 1 were considered “improved.”
Test–retest reliability substudy
To further evaluate the reliability of the UFS-QOL, a test–retest
reliability substudy was conducted. A block randomization
scheme of 1:4 for the FTG and 1:3 for the NCG was developed prior
to study initiation to randomize 100 FTG women and 30 NCG
women to participate in a test–retest reliability substudy. Partici-
pants were randomized upon return of their completed 6-month
follow-up questionnaires. Participants randomized to the retest
visit completed the retest visit approximately 2 weeks (14 days 2
days) after the 6-month follow-up visit. The retest questionnaire
packet was the same as the 6-month packet and were completed
and returned in the same manner as the others.
Sample size calculation and statistical analysis
An initial recruitment rate of 100 patients per group was
planned, based on the within-individual change over time for
the treatment groups and reported elsewhere [11]. Scoring of
the questionnaires was performed according to the developers’
guidelines. Analyses were performed on SAS version 9.1.3 (SAS
Institute Inc., Cary, NC); all statistical tests were identified a
priori and no data imputations were performed for missing data.
All statistical tests were two-tailed and were conducted with
Type I error probability fixed at 0.05.
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graphic and clinical characteristics. Additional psychometric
analyses were conducted on the UFS-QOL to examine internal
consistency reliability, and discriminant and concurrent validity.
A Cronbach’s alpha 0.70was considered to demonstrate internal
consistency [13]. Intraclass correlation coefficients (ICC) and
Spearman’s correlations were calculated to evaluate the degree of
association between mean UFS-QOL scores at the 6-month fol-
low-up and 2-week retest visit with scores of 0.70 considered ad-
equate test–retest reliability [14]. Spearman correlations were
used to evaluate convergent validity with a correlation range of
0.40 to 0.70 considered adequate.
Paired t-tests were used to evaluate whether there was statis-
tically significant change in scores on the UFS-QOL between the
test–retest evaluations. Questionnaire change scores, effect size
(ES), and standard error of measurement (SEM) from baseline to
the 6-month visit and from baseline to the 1-year visit were calcu-
lated by treatment group to determine the responsiveness of the
UFS-QOL. ES was interpreted as small (0.20), moderate (0.50), or
Table 1 – Baseline participant demographic characteristics
Characteristic NCG (N
Age (mean, SD years) 40.8 (4.9)
Race (n, % yes)
White 43 (42.6%
Black 49 (48.5%
Asian 1 (1.0%)
Hispanic 6 (5.9%)
Other* 1 (1.0%)
Missing 1 (1.0%)
Employment status (n, % yes)
Employed, full time 65 (64.4%
Employed, part time 18 (17.8%
Homemaker 13 (12.9%
Student 1 (1.0%)
Unemployed 2 (2.0%)
Disabled 1 (1.0%)
Highest level of education (n, % yes)
Elementary/primary school 0 (0.0%)
Secondary/high school 7 (6.9%)
Some college 26 (25.7%
College degree 35 (34.7%
Postgraduate degree 32 (31.7%
Comorbid medical conditions (n, % yes)
None 70 (69.3%
Arthritis 6 (5.9%)
Asthma 9 (8.9%)
Cancer 0 (0.0%)
COPD/emphysema 0 (0.0%)
Diabetes 1 (1.0%)
Heart problems 0 (0.0%)
Hypertension 7 (6.9%)
Other† 13 (12.9%
Height (mean, SD feet) 5.4 (0.2)(n
Weight (mean, SD pounds) 163.7 (37.7)(
Body mass index (mean, SD) 27.1 (6.1)(n
COPD, chronic obstructive pulmonary disease; FTG, fibroid treatmen
* Other includes American Indian and mixed race.
† Other includes Addison’s disease, allergies, anemia, anorexia, an
cervical dysplasia, Crohn’s disease, epilepsy, eczema, gastroesopha
hyperthyroidism, hypothyroidism, lupus, mitral valve prolapse, m
compulsive disorder, osteoporosis, polycystic kidney disease, pulmarthritis, sleep apnea, and spinal/neck degeneration.large (0.80) following the guidelines proposed by Cohen [15] in
1988. The SEM is computed by multiplying the standard deviation
of the measure by the square root of one minus its reliability co-
efficient. Scheffe’s post-hoc comparisons were performed for gen-
eral linear models with multiple statistical comparisons. Confir-
matory factor analyses (CFA) were performed on the previously
determined UFS-QOL subscales using EQS 6.1 (Build 90) for Win-
dows (Multivariate Software Inc., Encino, CA). Bentler’s confirma-
tory fit index (CFI) of  0.90 was used as the criteria to assess
goodness of model fit [16].
Results
Participants
A total of 101 women in the NCG and 274 women in the FTG com-
pleted the baseline packets. In the NCG, 89 (88%) subsequently
completed the 12-month follow-up visit. In the FTG, 274 com-
1) FTG (N  274) P value
43.1 (4.5) 0.0001
120 (43.8%) 0.6159
122 (44.5%)
7 (2.6%)
11 (4.0%)
10 (3.6%)
4 (1.5%)
217 (79.2%) 0.0061
20 (7.3%)
18 (6.6%)
1 (0.4%)
9 (3.3%)
9 (3.3%)
1 (0.4%) 0.3118
36 (13.1%)
79 (28.8%)
92 (33.6%)
66 (24.1%)
133 (48.5%) 0.0003
23 (8.4%) 0.4301
24 (8.8%) 0.9633
2 (0.7%) 0.3893
3 (1.1%) 0.2911
6 (2.2%) 0.4464
3 (1.1%) 0.2911
47 (17.2%) 0.0124
64 (23.4%) 0.0257
0) 5.4 (0.2) 0.1062
00) 168.9 (44.5) 0.3043
0) 28.2 (6.9)(n  273) 0.1529
p; NCG, normal control group; SD, standard deviation.
back problems, breast cancer, bulimia, chronic fatigue syndrome,
eflux disease, glaucoma, hepatitis C, high cholesterol, hypertension,
epression, Meniere’s disease, migraines, muscle tension, obsessive
y hyalinizing granulomas, recent foot and hand surgery, rheumatoid.
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138 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 5 – 1 4 2pleted the baseline packet; of these, 107 had embolization treat-
ment, 61 had a myomectomy, and 106 had a hysterectomy. There
were 89 (83%), 55 (90%), and 91 (86%) women who completed the
12-month follow-up visit within the embolization, myomectomy,
and hysterectomy groups, respectively.
The mean age of women in the FTG was significantly higher
than the women in the NCG (43.1 versus 40.8 years, P  0.001)
(Table 1). There were no significant differences between the
groups in terms of race or education. Women in the FTG were
slightly more likely to be employed full-time (P 0.0061), whereas
women in the NCG were more likely to report no comorbid condi-
tions (69.3% vs. 48.5%, P  0.0003) than the women in the FTG.
Among the NCG, the UFS-QOL item means ranged from 1.1 to
2.1, indicating a very low level of symptoms and HRQL impact
(Table 2). Within the FTG, the item means reflected greater sever-
ity and impact, ranging from 2.6 to 4.1 (Table 2). At baseline, all
individual itemmeans of the UFS-QOL were significantly different
Table 2 – Baseline comparison of UFS-QOL items for NCG a
UFS-QOL item
1. Heavy bleeding during your menstrual period
2. Passing blood clots during your menstrual period
3. Fluctuation in the duration of your menstrual period compared t
4. Fluctuation in the length of your monthly cycle compared to you
5. Feeling tightness or pressure in your pelvic area
6. Frequent urination during the daytime hours
7. Frequent nighttime urination
8. Feeling fatigued
9. Made you feel anxious about the unpredictable onset or duration
10. Made you anxious about traveling?
11. Interfered with your physical activities?
12. Caused you to feel tired or worn out?
13. Made you decrease the amount of time you spent on exercise or
activities?
14. Made you feel as if you are not in control of your life?
15. Made you concerned about soiling underclothes?
16. Made you feel less productive?
17. Caused you to feel drowsy or sleepy during the day?
18. Made you feel self-conscious of weight gain?
19. Made you feel that it was difficult to carry out your usual activiti
20. Interfered with your social activities?
21. Made you feel conscious about the size and appearance of your s
22. Made you concerned about soiling bed linen?
23. Made you feel sad, discouraged, or hopeless?
24. Made you feel down hearted and blue?
25. Made you feel wiped out?
26. Caused you to be concerned or worried about your health?
27. Caused you to plan activities more carefully?
28. Made you feel inconvenienced about always carrying extra pads,
to avoid accidents?
29. Caused you embarrassment?
30. Made you feel uncertain about your future?
31. Made you feel irritable?
32. Made you concerned about soiling outer clothes?
33. Affected the size of clothing you wear during your periods?
34. Made you feel that you are not in control of your health?
35. Made you feel weak as if energy was drained from your body?
36. Diminished your sexual desire?
37. Caused you to avoid sexual relations?
FTG, fibroid treatment group; NCG, normal control group; SD, sta
questionnaire.between the NCG and FTG (Table 2; all P 0.001). The difference in
means was largest (mean difference  2.5) for item 15 (made you
concerned about soiling underclothes) and item 28 (made you feel incon-
venienced about always carrying extra pads, tampons, and clothing to
avoid accidents). The smallest mean difference (1.4) was observed
for item 24 (made you feel downhearted and blue).
At baseline, all subscales of the UFS-QOL and SF-36 differed
significantly between the FTG and the NCG (all P 0.001) (Table 3),
with the FTG reporting significantly greater symptom severity and
lower HRQL on the UFS-QOL and SF-36. Comparisons among the
three FTGs revealed no significant differences at baseline, with the
exception of the mental health subscale of the SF-36 – the hyster-
ectomy group had a significantly worse mental health score when
compared with the UFE group (58.3 vs. 67.8, respectively; P 0.01).
Cronbach’s alphas were calculated for each UFS-QOL subscale
for the NCG, FTG, and also for each of the three FTGs. The alphas
ranged from 0.73 to 0.97 at baseline reflecting strong internal con-
TG.
Mean (SD) P value
NCG
(N  98)
FTG
(N  274)
1.8 (1.0) 4.1 (1.2) 0.0001
1.6 (0.9) 3.7 (1.3) 0.0001
r previous cycle 1.3 (0.6) 3.3 (1.4) 0.0001
ious cycles 1.4 (0.7) 3.3 (1.4) 0.0001
1.6 (0.9) 3.7 (1.2) 0.0001
1.6 (0.9) 3.5 (1.3) 0.0001
1.5 (0.9) 3.2 (1.4) 0.0001
2.1 (1.0) 3.9 (1.1) 0.0001
ur periods? 1.2 (0.6) 3.4 (1.3) 0.0001
1.2 (0.6) 3.2 (1.4) 0.0001
1.2 (0.6) 3.5 (1.2) 0.0001
1.5 (0.9) 3.8 (1.1) 0.0001
physical 1.3 (0.7) 3.6 (1.2) 0.0001
1.1 (0.4) 3.3 (1.4) 0.0001
1.5 (1.0) 4.0 (1.2) 0.0001
1.3 (0.6) 3.4 (1.2) 0.0001
1.4 (0.8) 3.3 (1.3) 0.0001
1.3 (0.7) 3.5 (1.4) 0.0001
1.2 (0.6) 3.3 (1.3) 0.0001
1.2 (0.4) 3.2 (1.3) 0.0001
ch? 1.4 (0.8) 3.8 (1.3) 0.0001
1.4 (0.8) 3.8 (1.3) 0.0001
1.2 (0.5) 2.7 (1.2) 0.0001
1.2 (0.6) 2.6 (1.2) 0.0001
1.4 (0.7) 3.4 (1.3) 0.0001
1.2 (0.6) 3.5 (1.1) 0.0001
1.2 (0.6) 3.4 (1.2) 0.0001
ons, and clothing 1.3 (0.7) 3.8 (1.3) 0.0001
1.1 (0.3) 2.8 (1.3) 0.0001
1.1 (0.5) 2.6 (1.3) 0.0001
1.4 (0.8) 3.4 (1.2) 0.0001
1.3 (0.8) 3.7 (1.3) 0.0001
1.2 (0.6) 3.3 (1.5) 0.0001
1.1 (0.4) 3.1 (1.3) 0.0001
1.4 (0.8) 3.6 (1.2) 0.0001
1.3 (0.8) 3.4 (1.3) 0.0001
1.6 (1.2) 3.2 (1.4) 0.0001
deviation; UFS-QOL, uterine fibroid symptom and quality-of-lifend F
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139V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 5 – 1 4 2sistency (Table 4). Internal consistency reliability was also very
good at the 6-month follow-up (range: 0.77–0.99) and 1-year fol-
low-up visits (range: 0.78–0.97).
Spearman’s correlations were used to assess the concurrent
validity of the UFS-QOL with the SF-36. Correlations among all
UFS-QOL HRQL subscales and the SF-36 ranged from 0.04 (con-
cern-role physical) to 0.40 (energy/mood-general health and con-
trol-physical component score) in the NCG and from 0.15 (self-
consciousness-general health) to 0.66 (control-social functioning)
in the FTG. Although the subscales on the UFS-QOL and SF-36
measure different domains, specific subscales of each scale are
better suited to evaluate concurrent validity. For example, the
UFS-QOL symptom severity subscale was moderately correlated
with the SF-36 bodily pain subscale (NCG: r –0.39; FTG: r –0.43).
Among women in the FTG, the symptom severity subscale was
also moderately correlated with each of the SF-36 subscales.
Each UFS-QOL subscale was responsive to changes in the FTG
condition with no significant change observed among the NCG
over time. As expected, therewere no significant changes in any of
UFS-QOL subscale scores in the NCG from baseline to 6-month
follow-up. Mean change scores ranged from 0.7 (concern) to 2.9
(energy/mood), with effect sizes ranging from 0.04 to 0.19 (Table 5).
The UFS-QOLwas highly responsive to treatment-related changes
among the FTG. In the FTG, the mean change score from baseline
at the 6-month follow-up for symptom severity was 43.7 (P 
0.001) representing an effect size of 2.18 and an SEM of 7.45 (Ta-
ble 5). Mean change scores for the HRQL subscales ranged from
35.3 (sexual function) to 50.8 (concern) with effect sizes between
Table 3 – UFS-QOL and SF-36 scores at baseline: NCG
versus FTG.
Mean (SD) P value
NCG
(N  98)
FTG
(N  274)
UFS-QOL
Symptom severity* 15.3 (14.5) 64.8 (20.0) 0.0001
Concern† 91.4 (16.8) 31.5 (27.9) 0.0001
Activities† 95.2 (10.8) 42.9 (26.2) 0.0001
Energy/mood† 90.9 (15.4) 43.5 (25.0) 0.0001
Control† 95.9 (8.9) 45.8 (26.4) 0.0001
Self-consciousness† 92.1 (15.1) 36.2 (29.3) 0.0001
Sexual function† 88.2 (24.6) 42.9 (31.9) 0.0001
HRQL total† 92.8 (11.7) 40.8 (22.1) 0.0001
SF-36†
Physical functioning 93.2 (15.5) 75.1 (26.0) 0.0001
Role physical 93.4 (19.8) 47.9 (41.9) 0.0001
Bodily pain 86.0 (16.1) 48.5 (24.3) 0.0001
General health 83.3 (13.4) 67.5 (20.4) 0.0001
Vitality 62.8 (18.0) 36.1 (21.5) 0.0001
Social functioning 90.3 (16.4) 62.4 (28.1) 0.0001
Role emotional 89.3 (23.8) 57.2 (42.8) 0.0001
Mental health 78.8 (12.9) 62.9 (19.8) 0.0001
Physical component
score
54.7 (5.9) 43.1 (9.6) 0.0001
Mental component
score
51.3 (7.2) 41.6 (11.3) 0.0001
FTG, fibroid treatment group; HRQL, health-related quality of life;
NCG, normal control group; SD, standard deviation; SF-36, short
form 36 health survey; UFS-QOL, uterine fibroid symptomand qual-
ity-of-life questionnaire.
* Scores range from 0 to 100; higher scores indicate greater symp-
tom severity.
† Scores range from 0 to 100; higher scores indicate better HRQL.1.1 and 1.8. At the 1-year follow-up, the pattern of responsivenessresults was similar to that observed at the 6-month follow-up.
Again, the NCG indicated no significant changes in any of the
scales, whereas the women in the FTG reported significant im-
provements in each of the scales (all P  0.001). When examining
the cumulative distribution curves at 6months for the FTG, 90% of
women who reported that they were doing “much better” on an
overall treatment effect scale also had a 20 point or greater im-
provement in the symptom severity scale versus 70% of women
reporting that they were “a little better” and 60% of women who
reported they were “no better or worse” (Fig. 1). Similar results
were noted at 1 year.
Twenty-nine women in the NCG and 59 women in the FTG
completed their retest questionnaires within 2 weeks of the
6-month follow-up visit. Of the 59 FTG women, only 8 women
reported being stable or unchanged during the 2-week retest pe-
riod, therefore the test–retest analysis could not be conducted
within this group. Test–retest reliability, however, was assessed in
the NCG group among the 26 normal women who reported to be
stable. The scores on the UFS-QOL subscales were largely stable
with change scores ranging between 0.6 (self-consciousness) and
8.5 (sexual function) (Table 6). A statistically significant change
was present in the energy/mood subscale and HRQL total; how-
ever, the change score for these two scales was 2.3 on a 0 to 100
scale, indicating very little change had occurred. The Spearman
correlations for the subscales ranged from 0.37 for the control sub-
scale to 0.84 for the sexual function subscale (all P  0.05, except
ontrol which was not significant) (Table 6). The low correlations
oted for both symptom severity (0.42) and control (0.37) are likely
ue to lack of variability in symptoms in this sample of normal
ontrol women.
The CFAs were performed using the uterine fibroid group data;
ormal controls were excluded from the CFA. The CFA confirmed
he factor structure of theUFS-QOL subscales and indicate that the
FS-QOL subscales of concern, activities, energy/mood, self-con-
cious, control, and sexual function fit the data very well with
entler’s CFI and all exceeded 0.90 (range: activities CFI  0.92 to
exual functioning and self-conscious CFI  0.99). The symptom
everity and energy subscales also fit the data well with CFIs of
.99 and 0.96, respectively, however, only after hierarchical latent
odels were used to improve fit.
Discussion
Assessing the impact of uterine fibroids in women has been an
ongoing challenge for researchers and clinicians. Women with
Table 4 – Internal consistency reliability (Cronbach’s
alpha) of the UFS-QOL at baseline.
UFS-QOL Number of
items (k)
Cronbach’s alpha
NCG
(N  98)
FTG
(N  274)
Symptom severity 8 0.82 0.79
Concern 5 0.90 0.92
Activities 7 0.90 0.92
Energy/mood 7 0.92 0.92
Control 5 0.73 0.89
Self-consciousness 3 0.87 0.80
Sexual function 2 0.84 0.91
HRQL total 29 0.95 0.96
FTG, fibroid treatment group; HRQL, health-related quality of life;
NCG, normal control group; UFS-QOL, uterine fibroid symptom and
quality-of-life questionnaire.
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heavy bleeding, menstrual cramps, and urinary frequency and
urgency that are also present to some degree among normal,men-
struating women. Although menstruating women have men-
strual symptoms that are captured by the UFS-QOL, the UFS-
QOL clearly differentiates between women with and without
fibroids, highlighting the profound impact that uterine fibroids
and associated symptoms have on HRQL. Additionally, this
study documented the responsiveness of the UFS-QOL to fibroid
treatment and also documented the stability of the UFS-QOL in
normal patients.
Table 5 – Responsiveness of the UFS-QOL.
UFS-QOL scale Normal controls
Mean change score* P value†
6 Months
Symptom severity§ 1.5 0.3654
Concern 0.7 0.5811
Activities 1.2 0.2708
Energy/mood 2.9 0.0510
Control 1.5 0.1136
Self-consciousness 2.1 0.1371
Sexual function 1.8 0.3427
HRQL total 1.7 0.1113
12 Months
Symptom severity§ 1.0 0.5218
Concern 2.0 0.1962
Activities 0.9 0.4290
Energy/mood 0.7 0.6328
Control 1.4 0.2066
Self-consciousness 2.7 0.0633
Sexual function 2.3 0.3654
HRQL total 1.4 0.2353
HRQL, health-related quality of life; UFS-QOL, uterine fibroid sympto
* Calculated as 6-month visit score minus baseline score; scores ran
† Paired t tests comparing responses at baseline and 6 months.
‡ Calculated as score difference divided by standard deviation of bas
§ Scores range from 0 to 100; higher scores indicate greater symptom
 Scores range from 0 to 100; higher scores indicate better HRQL.
Fig. 1 – The uterine fibroid symptom and quality of life ques
fibroid treatment group.The primary limitation in clinical research of uterine fibroids
has been the lack of outcome measures of the symptoms and as-
sociated condition-specific HRQL experienced by two important
groups, normal women in the same age range as fibroid patients
and women who undergo hysterectomy. Without data from these
benchmark groups, it is difficult to assess the comparative effec-
tiveness of other interventional or pharmacologic fibroid thera-
pies. The ability to compare the outcomes of uterus-sparing fibroid
therapieswith hysterectomy advances the use of patient-reported
outcomes in the field of fibroid therapy. Given that other studies
evaluating newer fibroid therapies have also used the UFS-QOL
Fibroid treatment group
t size‡ Mean change score* P value† Effect size‡
0.11 43.7 0.0001 2.18
0.04 50.8 0.0001 1.81
0.12 43.2 0.0001 1.66
0.19 39.0 0.0001 1.58
0.16 42.0 0.0001 1.61
0.15 42.4 0.0001 1.44
0.08 35.3 0.0001 1.11
0.15 42.7 0.0001 1.96
0.07 47.2 0.0001 2.35
0.12 54.8 0.0001 1.92
0.08 46.1 0.0001 1.77
0.05 41.5 0.0001 1.65
0.15 44.4 0.0001 1.69
0.18 42.4 0.0001 1.43
0.09 36.4 0.0001 1.14
0.12 45.2 0.0001 2.03
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m 100 to 100.
score.
rity.
aire symptom severity score change at month 6 in theEffec


m an
ge fro
eline
sevetionn
fi
l
w
t
141V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 5 – 1 4 2[7,8,10], having benchmark values among normal women as well
as post-hysterectomy women provides context for cross-study
evaluation as well as a common outcome tool that can be used for
future comparative effectiveness research. It should be noted that
theUFS-QOL offersmore information than the traditional pictorial
blood loss assessment diary [17], which has been used in many
broid studies as a measure of menorrhagia. The pictorial blood
oss assessment only captures information regarding blood loss
ithout assessing other fibroid symptoms (e.g., pain or bulk symp-
oms) or the impact of fibroid symptoms on HRQL.
The initial psychometric validation study of the UFS-QOL [5]
included an item reduction component to reduce the UFS-QOL
from 72 to 37 items. This is the first study to assess the validity,
reliability, and responsiveness of the final 37-item version of the
UFS-QOL. The CFA performed in this study confirmed the factor
structure of the final 37-item version of the UFS-QOL subscales. In
addition, only 29 normal controls and 110 women with uterine
fibroids were enrolled in the initial psychometric validation study.
A larger cohort of women with and without uterine fibroids was
enrolled in this study, which allowed for amore robust analysis of
validity and reliability, and an analysis of the responsiveness of
the UFS-QOL to treatment.
Although the UFS-QOL is highly responsive to the treatments
in this study, it is difficult to recommend a minimal important
difference (MID) that would define “responders” per se from this
interventional group. First, this analysis is limited in that only 5
women in the FTG reported that their condition was worse after
treatment whereas the vast majority of women experienced large
improvements in their UFS-QOL scores. Secondly, 90% of women
who responded that they were “much better,” reported a 20 point
or greater reduction in their symptom severity score of the UFS-
QOL. This overwhelming large positive response among women
with interventional treatments for their fibroidsmakes estimating
an MID problematic. An MID recommendation from this study
would likely be too high for pharmacologic treatments or other
non-interventional treatments.
The authors acknowledge the limitations of this study. This
study utilized a convenience sample of women with and with-
out uterine fibroids who were enrolled as they were scheduled
for uterine fibroid treatment (FTG) or presented to the office
(NCG). Treatment assignment was not randomized or blinded;
in fact, the women in this study not only knew but actively
selected the treatment they received, whichmay have produced
a bias in treatment outcome. Because scores across the three
Table 6 – Test–retest reliability of the UFS-QOL: normal con
UFS-QOL scale 6-month visit
score N  26
(mean, SD)
Retest visit
score N  26
(mean, SD)
Symptom severity§ 14.8 (14.0) 12.4 (12.8)
Concern 90.4 (22.4) 92.7 (17.6)
Activities 95.6 (11.0) 96.3 (9.5)
Energy/mood 92.7 (13.2) 95.1 (12.3)
Control 96.7 (7.9) 99.2 (2.3)
Self-consciousness 96.2 (9.5) 96.8 (9.5)
Sexual function 85.1 (28.5) 93.0 (12.5)
HRQL total 93.5 (11.8) 95.6 (9.8)
HRQL, health-related quality of life; UFS-QOL, uterine fibroid sympto
* Calculated as 6-month visit score minus baseline score; scores ran
† Paired t tests comparing responses at 6 months and retest visits.
‡ ^P  0.05; ^^P  0.01; ^^^P  0.001.
§ Scores range from 0 to 100; higher scores indicate greater symptom
 Scores range from 0 to 100; higher scores indicate better HRQL.fibroid treatment groups were similar [11], however, this islikely not the case. In addition, the test–retest analyses were
limited by the small sample of women who reported being sta-
ble or unchanged during the 2-week retest period. The sample
size in the FTG was not adequate to perform these analyses so
the analyses were only conducted within the NCG. Further eval-
uation of the test–retest reliability of the UFS-QOL in women
with fibroids who are not undergoing treatment is warranted.
Lastly, this study had been designed for 5 years of follow-up to
provide long-term data regarding each treatment group. Unfor-
tunately, with the loss of funding, the long-term data were not
captured and are still needed to evaluate long-term outcomes of
these fibroid treatments.
Despite these limitations, this study demonstrates the validity
and reliability of the UFS-QOL and the responsiveness of the UFS-
QOL to therapeutic change. The UFS-QOL is a valid and reliable
measure that can be utilized to assess and compare outcomes of
uterine fibroid therapies.
Source of financial support: This study was supported by a
grant from the US Army (USARMC Contract Number A-12818.2b
Gynecologic Disease Program).
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